Serum levels of progesterone and estradiol in menopausal women and users of hormonal contraceptives undergoing dental treatment

Adriana Della Giustina Perin1*, Amália Cinthia Meneses Rêgo2, Fausto Pierdoná Guzen2, Irami Araújo-Filho3, Ricardo Ney Cobucci3.

1Postgraduate Program in Biotechnology, Health School, Potiguar University (UnP) -Laureate International Universities –Natal, Rio Grande do Norte, Brazil.

2PhD, Full Professor of the Postgraduate Program in Biotechnology, Potiguar University (UnP)-Laureate International Universities –Natal, Rio Grande do Norte, Brazil.

3MD, PhD, Full Professor of the Postgraduate Program in Biotechnology, Potiguar University (UnP)-Laureate International Universities –Natal, Rio Grande do Norte, Brazil.

* Corresponding author: Email: rncobucci@unp.br

Keywords:

Progestrone
Estradiol
Menopause
Female contraceptives
Hormone replacement therapy

Abstract

Objectives: to assess whether women who are using hormonal contraceptives are at similar risk to menopause for oral problems related to falling levels of sexual hormones. Methods: serum estradiol and progesterone were measured to compare levels among women of childbearing age who use oral contraceptives or intrauterine devices with menopausal or hysterectomized women. The Mann-Whitney test was used to compare the plasma concentration of progesterone and estradiol between the groups and statistical significance was set
Serum levels of progesterone and estradiol in menopausal women and users of hormonal contraceptives undergoing dental treatment

at p<0.05. **Results**: fifty-two (52) women divided into two groups, 27 women aged 16 to 47 years, which used oral contraceptive methods or hormonal intrauterine device and 25 menopausal or hysterectomized women aged 45 to 76 years. Progesterone serum concentration (0.36 ± 0.13 ng / mL vs. 0.21 ± 0.03 ng / mL, p = 0.001) was significantly higher in the contraceptive group. The concentration of estradiol (19.8 ± 12.5 ng / mL vs. 15.2 ± 4.6 ng / mL, p = 0.263) was similar between the groups. **Conclusions**: women of childbearing age using hormonal contraceptives had similar estradiol levels to those of menopausal women. Low levels of this hormone may predispose to oral pathologies, so women should receive special attention at the dental care level.

**Introduction**

Oral health involves complex multifactorial relationships in which the endocrine system plays an important role.¹ Sexual hormones (SH) play a role in the proliferation, differentiation and growth of target cells in areas such as the alveolar bone, gingiva, ligament periodontal and root cementum. The modulation in SH levels during puberty, menstruation, pregnancy and menopause can influence the sensitivity to periodontal disease.²

The number of oral hormonal contraceptives (OHC) is increasing worldwide because of their use as a method of birth control and regulation of the menstrual cycle and ovulation.³ Studies have shown that OHC may predispose to gingival insertion and inflammation in the subgingival environment, culminating in periodontal disease⁴, which manifests as bleeding and greater depth of the periodontal pocket due to increased cellularity and increased gingival size.⁵

Menopause is the period in the lifetime of a woman where hormonal production of progesterone and estradiol decrease at the end of the fertile age. The decrease of hormonal levels directly affects the oral cavity, which is where the receptors for the hormones are present. Oral xerostomia, hyposalivation, ha-
litosis, bone postmortem, and periodontitis are signs and symptoms frequently associated with menopause. Reactions to OHC or the use of intrauterine devices (IUD), which include gingivitis and periodontal diseases, are very similar to those that occur in menopausal women.

Dental problems usually appear at times, such as pregnancy, puberty, and menopause, suggesting that hormonal changes may trigger these problems. The most frequently encountered problems are those found in menopause, which may be related to the fall in hormonal levels, especially estradiol.

The main objective of this study was to compare progesterone and estradiol serum levels among women of childbearing age who use oral contraceptive methods or hormonal IUD, with menopausal or hysterectomized women to assess whether women using contraceptive agents are at similar risk to menopausal women for oral pathologies.

**Methods**

This is a cross-sectional study involving 52 women (n = 52) who were treated in a private dental office between January 2016 and December 2017, and who underwent an initial dental evaluation which included a request for serum levels of estradiol and progesterone. The inclusion criteria for participation in the study were female, at a fertile age of over 16 years, using OHC or IUD with progesterone, and menopausal or hysterectomized women who had never had any hormone replacement therapy (HRT). Participants were separated into two groups. Group I: 27 participants (n = 27) of childbearing age using OHC or IUD and Group II: 25 (n = 25) women who were menopausal and hysterectomized for more than five years who had never had any HRT. There were no sample calculations in this study, including all the women who had submitted the dosage of estrogen and progesterone in a private laboratory of clinical analyzes.

This research was submitted and approved by the Potiguar
Results

Fifty-two (52) women were included in the study, 27 were allocated to the contraceptive group and 25 were in the menopausal group. Women in the contraceptive group were between 16 and 47 years of age, while in the menopausal group the ages ranged from 45 to 76 years, with mean and standard deviation (33.4 ± 8.0 vs. 61.9 ± 8.7 years, t (50) = -12.3, p<0.001), respectively. The concentration of progesterone (0.36 ± 0.13 ng / mL vs. 0.21 ± 0.03 ng / mL, U = 165, z = -3.199, p = 0.001) was significantly higher in the contraceptive group (Figure 1A). The concentration of estradiol (19.8 ± 12.5 ng / mL vs. 15.2 ± 4.6 ng / mL, U = 276.5, z = -1.199, p = 0.263) was similar between the groups (Figure 1B).

Figure 1. Progesterone and estradiol concentrations among users of contra-
Serum levels of progesterone and estradiol in menopausal women and users of hormonal contraceptives undergoing dental treatment

Figure 1A. Progesterone concentration. Figure 1B. Estradiol concentration. Data expressed in median and quartiles 25 and 75. * = statistically significant.

Among the 27 women who used contraceptive agents, 21 used oral contraceptives and six used IUD with progesterone. Among these women, the age was similar (32.0 ± 5.8 vs. 37.5 ± 7.0 years, U = 33, z = -1.753, p = 0.085), respectively. In addition, the concentration of progesterone (0.36 ± 11.5 vs. 0.35 ± 0.22 ng/mL, U = 66, z = 0.175, p = 0.877) and estradiol (18.0 ± 11.1 vs. 28.1 ± 15.3 ng/mL; U = 43.5; z = -1.139; p = 0.263) was not different (Figure 2).

Figure 2. Progesterone and estradiol concentrations among users of oral contraceptives and hormonal intrauterine devices (IUD). Figure 2A. Progesterone concentration. Figure 2B. Estradiol Concentration. Data expressed in median and quartiles 25 and 75.

Discussion

This study evaluated the hormonal levels of women using contraceptive agents to verify the possible hormonal changes that occurred when using these contraceptive methods and found that there is no statistically significant difference among menopausal or hysterectomized women and users of contraceptives containing estrogen and progesterone, concerning serum estradiol levels.

Estrogen has significant actions in the oral cavity. Receptors for estrogen are in the gingiva, fibroblasts, osteoblasts, and periodontal ligaments. Women with low levels of estrogen tend to present more dental pain, greater gingival recession, dental mobility, and bone loss.9 The findings of this study demonstrate that women who use hormonal contraceptives had similar levels of estradiol to that of menopausal women.

There is a natural decline in steroid hormones that may lead to increased inflammatory processes, loss of bone matrix deposition, decreased protein activity and decreased tissue lubrication during me-
Serum levels of progesterone and estradiol in menopausal women and users of hormonal contraceptives undergoing dental treatment

...nopause. These hormones also play a significant role in maintaining bone mass, influencing bone mineral metabolism, inducing proliferation of fibroblasts and keratinocytes and increasing the synthesis of fibrous collagen.

A study with estrogen-deficient female mice demonstrated that hormone deficiency leads to loss of mandibular bone. Os- teoblasts exhibit estrogen receptors that could explain the direct action of this hormone on the bone.

Systemic bone loss is an essential effect of decreasing levels of estradiol. The deficiency of this hormone leads to the positive regulation of immune cells (macrophages and monocytes) and osteoclasts, responsible for higher production of cytokines of bone resorption.

The sub-products released by lipopolysaccharides related to periodontal tissues and bacterial plaque biofilms stimulate the production of inflammatory cytokines, which further activate osteoclasts that reabsorb the bone. Interleukins and Tumor Necrosis Factor (TNF) promote osteoclastic stimulation. In this study, women of childbearing age using OHC had similar serum levels of estradiol to that of menopausal women, and this may predispose them to the appearance of dental disorders.

Progesterone is active in bone metabolism and has a significant effect on bone formation through direct involvement of osteoblast receptors. This hormone promotes the increase of vascular dilatation on periodontal tissues, increasing prostaglandin E2 in the gingival fluid. In addition, it can produce reduction of glucocorticoid anti-inflammatory effect, inhibition of collagen synthesis in periodontal ligament fibroblasts, alteration of the rate and pattern of collagen production in the gingiva, resulting in increased metabolic degradation of folate, necessary for the maintenance and repair of the tissues.

The systemic response of an organism to periodontal infections varies individually and depends on the individual’s lipid composition. Progestin, for example, decreases HDL when compared to natural progesterone,
which does not affect levels of this lipoprotein whereas estradiol can inhibit LDL oxidation, which can interfere with osseointegration of dental implants.\textsuperscript{18,19}

According to Krysiaka et al\textsuperscript{20}, the use of OHC is a risk factor for numerous oral and systemic complications. Patients using OHC present more gingival inflammation with greater bleeding in periodontal probing regardless of the amount of bacterial plaque.\textsuperscript{5} This fact places these women at risk of contracting oral pathologies triggered by the drop-in levels of estradiol.

This study has some limitations: the small sample, the cross-sectional character of the study and the impossibility of associating oral pathologies with the hormonal levels.

Future research on oral pathologies related to the fall in hormone levels should prospectively assess, in a larger sample and with strict control of confounding bias, the association of reduced serum levels of estradiol and progesterone with disorders in the oral cavity.

Women of childbearing age who use OHC or IUD with progesterone have serum estradiol levels like those in menopausal or hysterectomized women. The numerous oral pathologies that can occur due to changes in hormonal levels, such as the drop-in estradiol serum concentration, place patients who use contraceptive agents at risk of complications in teeth, gums and other places in the oral cavity.

**Funding sources**

None

**Conflicts of interest**

None declared
Serum levels of progesterone and estradiol in menopausal women and users of hormonal contraceptives undergoing dental treatment

References

Bharadwaj P, Akintomide H, Brima N, Copas A, D’Souza R. Determinants of long-acting reversible contraceptive use by adolescent girls and young women. Eur J Contracept Reprod Health Care 2012;17(4):298-306.

Csányi A, Bóta J, Falkay G, Gáspár R, Ducza E. The effects of female sexual hormones on the expression of aquaporin 5 in the late-pregnant rat uterus. Int J Mol Sci. 2016; 17(8):1300

Deepa, MS. Women, hormones, and oral health. International Journal of Women’s Dental Council 2013;1:15-20

Domingues RS, Ferraz BF, Greghi SL, Rezende ML, Passanezi E, Sant’Ana AC. Influence of combined oral contraceptives on the periodontal condition. J Appl Oral Sci. 2012;20(2):253-9.

Farronato G, Maspero C, Folegatti C, Giannini L. Menopause: changes in the mouth cavity and preventive strategies. Journal of Women’s Health Care. 2012;1(1):102.

Grover CM, More VP, Singh N, Grover S. Crosstalk between hormones and oral health in the mid-life of women: a comprehensive review. J Int Soc Prev Community Dent. 2014;4(1):5-10.

Güncü, GN., Tözön, TF, Caglayan, F. Effects of endogenous sex hormones on the periodontium – review of literature. Aust Dent J. 2005;50(3):138-145.

Haro A, Saxlin T, Suominen AL, Jula A, Knuuttila M, Ylöstalo P. Serum lipids modify periodontal infection - interleukin-6 association. J Clin Periodontol. 2017;44(3):275-282.

Krysiaka R; Gilowskaa M; Okopieña B. The effect of oral contraception on risk factors in women with elevated androgen levels. Pharmacol Rep. 2017; 69(1):45 49.

Lieberman A, Curtis L. In Defense of Progesterone: A Review of the Literature. Altern Ther Health Med. 2017;23(6):24-32.

López JF, García VS, García AA. Periodontal aspects in menopausal women undergoing hormone replacement therapy. Med Oral Patol Oral Cir Bucal. 2005;10(2):132-41.
Serum levels of progesterone and estradiol in menopausal women and users of hormonal contraceptives undergoing dental treatment

Mariotti A, Mawhinney M. Endocrinology of sex steroid hormones and cell dynamics in the periodontium. Periodontol 2000. 2013;61(1):69-88.

Mariotti AJ. Estrogen and extracellular matrix influence human gingival fibroblast proliferation and protein production. J Periodontol. 2005;76(8):1391-1397.

Mullally BH, Coulter WA, Hutchinson JD, Clarke HA. Current oral contraceptive status and periodontitis in young adults. J Periodontol. 2007;78(6):1031-1036.

Nirola A, Batra P, kaur J. Ascendancy of sex hormones on periodontium during reproductive life cycle of women. Journal of International Clinical Dental Research Organisation. 2018;10(1):3-11.

Ramamurthy J. Role of estrogen and progesterone in the periodontium. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2015; 6(4):1540-1547.

Routley CE, Ashcroft GS. Effect of estrogen and progesterone on macrophage activation during wound healing. Wound Repair Regen. 2009;17(1):42-50.

Suri V. Menopause and oral health. J Midlife Health. 2014;5(3):115-20.

Uzui H, Sinha SK, Rajavashisth TB. 17β-estradiol inhibits oxidized low-density lipoprotein-induced increase in matrix metalloproteinase-9 expression in human macrophages. J Investig Med. 2011;59(7):1104-8.

Vanderschueren D, Laurent MR, Claessens F, Gielen E, Lagerquist MK.

Vandenput L, et al. Sex steroid actions in male bone. Endocr Rev. 2014;35(6):906-60.